Interferon-α2b improves short-term survival in patients transplanted for chronic liver failure caused by hepatitis B

Journal of Viral Hepatitis

Volumn 3, Issue 6, 1996, Pages 333-340

  Hassanein, T ^a   Colantoni, A ^a   De Maria, N ^a   Van Thiel, D H ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

HBV; Interferon; Survival; Transplantation

Indexed keywords

ALPHA2B INTERFERON; VIRUS DNA;

ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MIDDLE AGED; MORTALITY; SURVIVAL; TIME;

DNA, VIRAL; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MIDDLE AGED; SURVIVAL; TIME FACTORS;

EID: 0030280367     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.1996.tb00107.x     Document Type: Article

References (37)

1. Stremmel W, Schwartzendrube J, Nederau C, Strohmeyer G. Epidemiology, clinical course and treatment of chronic viral hepatitis. Hepatogastroenterology 1991; 31: 22-27.
2. O'Grady JG, Williams R. Liver transplantation for viral hepatitis. Br Med Bull 1990; 46: 481-491.
3. Todo S, Demetris AJ, Van Thiel DH, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991; 13: 619-626.
4. Lauchart W, Muller R, Pichlmayr R. Immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987; 19: 2387-2389.
5. Reynes M, Zignego L, Samuel D et al. Graft hepatitis delta reinfection after orthotopic liver transplantation in HDV cirrhosis. Transplant Proc 1989; 21: 22424-22245.
6. Colledan M, Grendele M, Gridelli B et al. Long term results after liver transplantation in B and delta hepatitis. Transplant Proc 1989; 21: 2421-2423.
7. Gordon RD, Todo S, Tzakis AG et al. Liver transplantation under cyclosporine: a decade of experience. Transplant Proc 1991; 23: 1393-1396.
8. Hoffnagle JH, Peters MG, Mullen CD et al. Randomized controlled trial of a four-month course of recombinant human alpha interferon in chronic type B hepatitis. Gastroenterology 1988; 95: 1318-1325.
9. Davis GL, Hoffnagle JH. Interferon in viral hepatitis. Hepatology 1986; 6: 1038-1041.
10. Thomas HC, Scully LJ. Antiviral therapy in chronic hepatitis B virus infection. Br Med Bull 1986; 41: 374-380.
11. Hoffnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alpha for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 1116-1121.
12. Korenman J, Baker B, Waggoner J et al. Long term remission of chronic hepatitis B after alpha interferon therapy. Am Int Med 1991; 114: 629-634.
13. Neuhaus P, Stiffer R, Blumbardt G et al. Experience with immunoprophylaxis and interferon therapy after liver transplantation in HBsAg positive patients. Transplant Proc 1991; 23: 1522-1524.
14. Iwatsuki S, Shaw BW Jr, Starzl TE. Current status of hepatic transplantation. Semin Liver Dis 1983; 3: 173-180.
15. Kuhns M, McNamara A, Cabel C et al. A new assay for the quantitative detection of hepatitis B viral DNA in human serum. In: Zuckerman A, ed. Viral Hepatitis and Liver Disease. New York: Alan R. Liss, 1988: 258-262.
16. Kuhns M, McNamara A, Perrillo et al. Quantitation of hepatitis B viral DNA by solution hybridization: comparison with DNA polymerase and hepatitis B e antigen during antiviral therapy. J Med Virol 1989; 27: 274-281.
17. Snedecor GW, Cochran WG. Statistical Methods. 6th edn. Ames, Iowa: The Iowa State University Press, 1967.
18. Lehmann EL. Nonparametrics. San Francisco, California: Holden-Day, Inc., 1975.
19. Petro R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
20. Parsons-Smith B, Summerskill W, Dawson A, Sherlock S. The electroencephalograph in liver disease. Lancet 1957; 2: 867-871.
21. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesephageal varices. Br J Surg 1973; 60: 646-669.
22. Rakela J, Wooten RS, Batts KP, Perkins JD, Taswell HF, Kron RAF. Failure of interferon to prevent recurrent hepatitis B infection in hepatic allograft. Mayo Clin Proc 1989; 64: 42932.
23. Marcellin P, Samuel D, Areias J et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B related endstage liver disease. Hepatology 1994; 15: 6-12.
24. Perrillo R, Regenstein F, Peterson M et al. A randomized controlled trial of prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. Ann Intern Med 1988; 109: 95-100.
25. Di Bisceglie AM, Rustgi VK, Kassianides C et al. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 1990; 11: 266-270.
26. Jicha DL, Davis GL, Peters MG, Hoffnagle JH, Jones EA. Effects of recombinant human leukocyte interferon treatment of endogenous interferon production in patients with chronic type-B hepatitis. J Interferon Res 1986; 6: 13-20.
27. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal or the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323: 295-301.
28. Thomas HC. Treatment of hepatitis B viral infection. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R. Liss, 1988: 817-822.
29. Thomas HC, Pignatelli M, Goodall A et al. Immunologic mechanisms of cell lysis in hepatitis B virus infection. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral Hepatitis and Liver Disease. Orlando, Florida: Grun and Stratton, 1984: 167-177.
30. Pignatelli M, Waters J, Brown D et al. HLA Class I antigens on hepatocyte membrane: expression during interferon therapy of chronic hepatitis B. Hepatology 1989; 6: 349-353.
31. Thomas HC, Pignatelli M, Lever. AML homology between HBV DNA and a sequence regulating the interferon induced antiviral system: possible mechanism of persistent infection. J Med Virol 1986; 19: 63-69.
32. Ameglio F, Capobianchi MR, Dolei A, Tosi R. Differential effects of gamma interferon on expression of HLA Class II molecules controlled by the DR and DC loci. Infect Immun 1983; 42: 122-125.
33. Herberman RB. Interferon and cytotoxic effector cells. In: Vilcek J, DeMaeyer E, eds. Interferon. Vol. 2. Interferons and the Immune System. Amsterdam: Elsevier Science Publishers, 1984: 61-84.
34. Oh SH, Gonish B, Greenberg SB, Kohl SJ. Enhancement of human neonatal natural killer cytotoxicity to herpes simplex virus with use of recombinant human interferons: lack of neonatal response to gamma interferon. J Infect Dis 1986; 153-163.
35. De Maeyer E, De Maeyer-Guignard TI. Interferon effects on cellular and humoral immunity. In: Baron S, Dianzani F, Stanton GL, Fleishmann WR Jr, eds. The Interferon System: A Current Review to 1987. Austin: University of Texas Medical Branch Series in Biomedical Science, 1987: 327-335.
36. Yoo YK, Gavaler JS, Chen MC et al. Alpha interferon: its effect upon lymphocyte subpopulations and HLD-Dr expression within the liver. Dig Dis Sci 1989; 1758-1864.
37. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.